ABSTRACT

Uterine malignancies have a good overall prognosis. The majority of patients present with early stages of the disease and are cured with surgery and radiotherapy. Chemotherapy predominantly has been employed in the management of advanced or recurrent disease where the aim of treatment is usually palliative. The median overall survival in this setting is 7-10 months. Medical oncologists increasingly use chemotherapy for clinical benefit even if this may have little influence on overall survival. Subsequently assessment of quality of life with minimization of toxicity becomes as important as both response rate and survival in evaluating new therapies.